Guest: Richard Kim, MD 


 Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Richard Kim, MD Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient. Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

How mCRC Tumor Sidedness Guides Treatment Decisions

According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.

Share How mCRC Tumor Sidedness Guides Treatment Decisions

Sign up to save your podcasts

How mCRC Tumor Sidedness Guides Treatment Decisions

How mCRC Tumor Sidedness Guides Treatment Decisions